Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study ; volume:13 ; number:1 ; day:16 ; month:10 ; year:2013 ; pages:1-8 ; date:12.2013
BMC neurology ; 13, Heft 1 (16.10.2013), 1-8, 12.2013
- Urheber
-
Balak, Deepak MW
- Beteiligte Personen und Organisationen
-
Hengstman, Gerald JD
Hajdarbegovic, Enes
van den Brule, Rob JP
Hupperts, Raymond MM
Thio, Hok Bing
SpringerLink (Online service)
- DOI
-
10.1186/1471-2377-13-146
- URN
-
urn:nbn:de:1111-2016030332144
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Balak, Deepak MW
- Hengstman, Gerald JD
- Hajdarbegovic, Enes
- van den Brule, Rob JP
- Hupperts, Raymond MM
- Thio, Hok Bing
- SpringerLink (Online service)
Ähnliche Objekte (12)
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Disease-modifying treatments in Alzheimer’s disease
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
Disease-modifying effects of metabolic perturbations in ALS/FTLD